Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202702 | 0.87 | CA12 (0.62) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL1278720 | 0.87 | NPC1 (0.68) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL2810136 | 0.87 | NPC1 (0.68) | NPC1LMNACYP1A2CYP3A4MAOA | |
| Hydrochloric Acid SCHEMBL9156219 | 0.85 | NPC1 (0.66) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL24527151 | 0.82 | CA12 (0.56) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL584117 | 0.82 | NPC1 (0.62) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL330220 | 0.81 | NPC1 (0.60) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL6264809 | 0.81 | CA12 (0.76) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL670880 | 0.81 | CA12 (0.55) | NPC1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL24526854 | 0.81 | CA12 (0.55) | NPC1LMNACYP1A2CYP3A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4308554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | The Board of Trustees of the University of Illinois (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197658-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| EP-3312177-B1 | TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ONCONIC THERAPEUTICS INC (KR) | 2021-04-14 | — | — | EP | disclosed |
| EP-3312177-B1 | TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ONCONIC THERAPEUTICS INC (KR) | 2021-04-14 | — | — | EP | disclosed |
| CN-107849040-B | Tricyclic derivative compound, preparation method thereof, and pharmaceutical composition containing the same | 肿瘤学治疗公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-2535327-A1 | Insecticidal 3-acylaminobenzanilides | Bayer CropScience AG (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| US-7964735-B2 | Insecticidal 3-acylaminobenzanilides | BAYER CROPSCIENCE AG (DE) | 2011-06-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090215623-A1 | Insecticidal 3-acylaminobenzanilides | BAYER CROPSCIENCE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1912933-A1 | INSECTICIDAL 3-ACYLAMINOBENZANILIDES | Bayer CropScience AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017075-A1 | INSECTICIDAL 3-ACYLAMINOBENZANILIDES | BAYER CROPSCIENCE AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | NPC1 474/4885LMNA 1174/4885CYP1A2 72/4885 |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NPC1 78/4885LMNA 4194/4885CYP1A2 399/4885 |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NPC1 78/4885LMNA 4194/4885CYP1A2 399/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | NPC1 1214/4885LMNA 3943/4885CYP1A2 46/4885 |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | NPC1 153/4885LMNA 2384/4885CYP1A2 169/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | NPC1 17/4885LMNA 1105/4885CYP1A2 928/4885 |
| US-20090215623-A1 | Insecticidal 3-acylaminobenzanilides | CBR3, AADAC, DDT | NPC1 1723/4885LMNA 2989/4885CYP1A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.